Assuntos
Histamina , Transtornos de Enxaqueca , Consumo de Bebidas Alcoólicas , Bebidas Alcoólicas , Etanol , HumanosRESUMO
BACKGROUND: Obesity is associated with non-alcoholic fatty liver disease (NAFLD), and the patatin-like phospholipase 3 (PNPLA3) rs738409 (Ile148Met, C>G) gene polymorphism is one of the most important genetic determinants of NAFLD. Carriers have been reported to better respond to lifestyle modification. AIM: To investigate the effect of rs738409 on overweight/obese adolescents and adults with and without metabolic syndrome (MetS). METHODS: Two hundred and eighty-eight overweight/obese and 209 normal weight participants of the STYJOBS/EDECTA cohort (NCT00482924) were analysed for PNPLA3 genotypes. RESULTS: Compared to overweight/obese without MetS, in overweight/obese study participants with MetS, the presence of the G allele (148Met) was significantly higher (CC: 5.0% vs. 9.2%, Spearman's correlation, 0.12; P = 0.038). Persons with CG (heterozygote for the risk allele) and with GG (homozygote for the risk allele) genotypes showed significantly higher ALT levels than those with CC genotypes. Even young individuals aged below 20 years had significantly increased ALT levels if they were homozygote with the G allele. CONCLUSIONS: The PNPLA3 rs738409 polymorphism is associated already in youths with increased ALT, and is more frequent in obese with MetS of all ages. Hence, overweight/obese rs738409 carriers should be identified early in life and treated with a rigorous life style intervention.
Assuntos
Lipase/genética , Proteínas de Membrana/genética , Síndrome Metabólica/complicações , Hepatopatia Gordurosa não Alcoólica/genética , Obesidade/genética , Adolescente , Adulto , Idoso , Alelos , Estudos de Casos e Controles , Criança , Feminino , Genótipo , Heterozigoto , Humanos , Estilo de Vida , Masculino , Síndrome Metabólica/genética , Pessoa de Meia-Idade , Obesidade/complicações , Polimorfismo Genético , Estudos Prospectivos , Adulto JovemRESUMO
Primary epiploic appendagitis (PEA) is a rare cause of abdominal acute or subacute complaints. Diagnosis of PEA is made when computed tomography (CT) reveals a characteristic lesion. We report on contrast-enhanced CT images of a patient with PEA and regression of inflammation and the reduction in size of the inflamed appendage over the time period of 4 months. Patients with PEA usually recover without medication or surgical treatment within a few weeks. However, due to continuing bloating and irregular bowel movements we investigated carbohydrate malabsorption and diagnosed a fructose malabsorption. Bloating and irregular bowel movements in this patient with PEA were correlated to carbohydrate malabsorption and were treated successfully with a diet free of culprit carbohydrates.
Assuntos
Dor Abdominal/etiologia , Frutose/efeitos adversos , Síndromes de Malabsorção/patologia , Doenças Peritoneais/patologia , Adulto , Humanos , Síndromes de Malabsorção/diagnóstico , Síndromes de Malabsorção/terapia , Masculino , Doenças Peritoneais/diagnóstico , Doenças Peritoneais/terapia , Tomografia Computadorizada por Raios XRESUMO
Invasive fungal infections (IFIs) in patients with haematological malignancies are difficult to diagnose and outcome is often fatal. Over the 7-month study period, 117 cases with haematological malignancies receiving systemic antifungal treatment were included. Data regarding antifungal agents, dosage and reason for administration were recorded. Fungal infections in study patients were classified as possible, probable or proven according to recent European Organization for Research and Treatment of Cancer criteria. During the study period, 690 cases with haematological malignancies were admitted. A total of 117 cases received systemic antifungal therapy. Twenty-four of 117 patients (21%) had possible, six (5.1%) had probable and four (3.4%) had proven IFI. Seven of 10 probable and proven infections were caused by Candida spp., 2 by Aspergillus spp. and 1 by a fungus belonging to Zygomycetes. Fifty-two of 117 patients (44%) received antifungal prophylaxis, 81 of 117 (69%) received empirical (31/117; 26%) or pre-emptive (50/117; 43%) antifungal therapy and four of 117 patients (3.4%) directed antifungal therapy. Mostly, systemic antifungal therapy was administered empirically or pre-emptively. Twenty-nine per cent of cases receiving systemic antifungal treatment met the international consensus criteria of mostly possible IFI, whereas 71% did not. Proven invasive fungal infections were rare.
Assuntos
Antifúngicos/uso terapêutico , Fungos/classificação , Fungos/isolamento & purificação , Neoplasias Hematológicas/complicações , Micoses/tratamento farmacológico , Micoses/epidemiologia , Adulto , Idoso , Quimioprevenção/métodos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos ProspectivosRESUMO
AIM: Somatostatin receptor scintigraphy images various neoplastic, granulomatous, and auto-immune diseases. Cat-scratch disease in an infectious granulomatous disease usually affecting the lymphnodes. It is not known whether cat-scratch disease provides positive somatostatin receptor scintigrams. PATIENTS, METHODS: Twelve patients with lymphadenitis and suspected cat-scratch disease were investigated by immunofluorescence antibody testing and somatostatin receptor scintigraphy. Suppurated lymphnodes were extracted or drained and Bartonella henselae specific PCR was then performed. RESULTS: Eleven of 12 patients showed IgG antibodies against B. henselae. SRS showed positive scintigraphic results in 6 of 11 patients with CSD. B. henselae DNA was detected in tissue of lymphnodes from 4 of 5 patients with lymphnode extraction or lymphnode drainage. SRS demonstrated positive scintigrams in all patients with a positive PCR. In one patient with suspected CSD SRS was negative as well as antibody testing. CONCLUSION: Somatostatin receptor scintigraphy correlated with positive Bartonella henselae specific PCR tests and positive Bartonella henselae specific antibody tests in patients with CSD.
Assuntos
Doença da Arranhadura de Gato/complicações , Linfadenite/diagnóstico por imagem , Receptores de Somatostatina/análise , Animais , Portador Sadio , Doença da Arranhadura de Gato/transmissão , Gatos , Humanos , Linfadenite/etiologia , Reação em Cadeia da Polimerase/métodos , Cintilografia , Receptores de Somatostatina/genética , Testes Cutâneos/efeitos adversosAssuntos
Ceco/anormalidades , Esvaziamento Gástrico/fisiologia , Intestino Delgado/anormalidades , Adulto , Ceco/diagnóstico por imagem , Ceco/cirurgia , Feminino , Humanos , Intestino Delgado/diagnóstico por imagem , Intestino Delgado/cirurgia , Cintilografia , Tecnécio , Tomografia Computadorizada por Raios X , Resultado do TratamentoRESUMO
Weight cycling may cause a redistribution of body fat to the upper body fat compartments. We investigated the distribution of subcutaneous adipose tissue (SAT) in 30 overweight women with a history of weight-cycling and age-matched controls (167 normal weight and 97 overweight subjects). Measurements of SAT were performed using an optical device, the Lipometer. The SAT topography describes the thicknesses of SAT layers at 15 anatomically well-defined body sites from neck to calf. The overweight women with a history of weight cycling had significantly thicker SAT layers on the upper body compared to the overweight controls, but even thinner SAT layers on their legs than the normal weight women. An android fat pattern was attributed to overweight females and, even more pronounced, to the weight cyclers. The majority of normal weight women showed a gynoid fat pattern. Using stepwise discriminant analysis, 89.0% of all weight cyclers and overweight controls could be classified correctly into the two groups. These findings show the importance of normal weight maintenance as a health-promoting factor.
Assuntos
Tecido Adiposo/patologia , Peso Corporal , Obesidade/patologia , Adulto , Idoso , Antropometria , Composição Corporal , Índice de Massa Corporal , Análise Discriminante , Feminino , Humanos , Pessoa de Meia-Idade , Obesidade/fisiopatologia , Aumento de Peso , Redução de PesoRESUMO
AIMS: To evaluate the determination of HbA(1c) with an automated high performance liquid chromatography (HPLC) method in patients with clinically silent haemoglobin variants. METHODS: HbA(1c) values were determined with the ion exchange HPL Bio-Rad Variant II using the high resolution beta thalassaemia programme in patients with silent haemoglobin variants, namely: Hb Graz, Hb Sherwood Forest, Hb O Padova, and Hb D. RESULTS: All of these haemoglobin variants caused additional peaks in the chromatograms. No clinically useful HbA(1c) results were produced for patients with Hb Graz and Hb Sherwood Forest, the results for the patient with Hb D were too low, but the results for patients with Hb O Padova were acceptable. CONCLUSIONS: The development of this automated HPLC method modification with high resolution mode aids the identification of interference caused by the described clinically silent haemoglobin variants in HbA(1c) determination.
Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Hemoglobinas Glicadas/análise , Hemoglobinas Anormais/análise , Artefatos , HumanosRESUMO
We describe a severe and recurrent septicemia due to Campylobacter in a 75-year-old immunocompetent patient. Two Campylobacter strains were detected in several blood cultures. Campylobacter fetus and Campylobacter lari were identified with PCR tests based on species-specific nucleotide sequences for the 16S rRNA gene.
Assuntos
Bacteriemia/diagnóstico , Infecções por Campylobacter/diagnóstico , Campylobacter fetus/isolamento & purificação , Imunocompetência , Idoso , Antibacterianos , Bacteriemia/tratamento farmacológico , Bacteriemia/imunologia , Campylobacter/classificação , Infecções por Campylobacter/tratamento farmacológico , Infecções por Campylobacter/imunologia , Quimioterapia Combinada/administração & dosagem , Seguimentos , Humanos , Masculino , Reação em Cadeia da Polimerase/métodos , RNA Bacteriano/análise , Recidiva , Índice de Gravidade de Doença , Resultado do TratamentoRESUMO
BACKGROUND: Percutaneous transluminal angioplasty (PTA) is routine treatment for patients with peripheral arterial disease (PAD). The procedure induces local generation of reactive oxygen species (ROS), such as H2O2. Since these have been shown to stimulate vascular smooth muscle cell growth (VSMCG), we investigated peroxide levels in patients with PAD during PTA and related these results to late clinical outcome. METHODS: Thirty patients (17 male, 13 female, 20 Fontain stage II, 10 Fontaine stage IV, median age 68 years) undergoing PTA of a 2-6 cm stenosis of the femoral or popliteal artery were included. The procedure was performed successfully in all patients. At follow-up six months thereafter restenosis was evaluated by duplex sonography. Total peroxide concentrations were determined in plasma drawn before, 6, 24 and 48 hours after the procedure by the Operoxide activityO assay, which is based on the reaction of horseradish peroxidase with plasma peroxides, using tetramethylbenzidine as the chromogenic substrate. RESULTS: The median peroxide level before angioplasty was 280 mmol/L (range 47-549). Levels were higher in patients with advanced disease, in smokers and in patients with diabetes. In response to angioplasty, peroxide levels increased within 48 hours (p<0.001). Six months after the procedure, restenosis was observed in 10/30 (33 percent) of patients. Clinical outcome was not dependent upon baseline or postinterventional peroxide levels. CONCLUSIONS: Elevated peroxide levels are seen in patients with advanced arteriosclerotic disease and in those with diabetes, but are not predictive for late restenosis.
Assuntos
Angioplastia com Balão , Oclusão de Enxerto Vascular/etiologia , Estresse Oxidativo/fisiologia , Idoso , Idoso de 80 Anos ou mais , Índice de Massa Corporal , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Doenças Vasculares Periféricas/sangue , Doenças Vasculares Periféricas/complicações , Doenças Vasculares Periféricas/terapia , Peróxidos/metabolismo , Fatores de Risco , Fatores de Tempo , Grau de Desobstrução VascularAssuntos
Angioplastia , Constrição Patológica/cirurgia , Fatores de Crescimento Endotelial/sangue , Linfocinas/sangue , Idoso , Idoso de 80 Anos ou mais , Arteriopatias Oclusivas/sangue , Arteriopatias Oclusivas/tratamento farmacológico , Arteriopatias Oclusivas/cirurgia , Constrição Patológica/sangue , Constrição Patológica/tratamento farmacológico , Humanos , Pessoa de Meia-Idade , Fator A de Crescimento do Endotélio Vascular , Fatores de Crescimento do Endotélio VascularRESUMO
Measurement of glycated hemoglobin in diabetic patients is an established procedure for evaluating long-term control of diabetes. The Diabetes Control and Complications Trial (DCCT), as well as the United Kingdom Prospective Diabetes Study (UKPDS), confirmed the direct relationship between the degree of glycemic control as estimated by glycohemoglobin (GHb) determinations and the development and progression of long-term complications in diabetic patients. Samples with known interferences of HbA(1c) determination as hemoglobinopathies are specifically excluded from certification testing and there are no guidelines or requirements for comparability of samples containing hemoglobin (Hb) variants. This paper reviews the interference of Hb variants on determination methods of glycated hemoglobin as they result in false HbA(1c) results.
Assuntos
Glicemia/metabolismo , Hemoglobinas Glicadas/análise , Hemoglobinas Anormais/análise , Hemoglobinas/genética , Biomarcadores/sangue , Variação Genética , Hemoglobinas Anormais/genética , HumanosAssuntos
Arteriopatias Oclusivas/sangue , Fatores de Crescimento Endotelial/sangue , Linfocinas/sangue , Estresse Oxidativo/fisiologia , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Humanos , Peróxido de Hidrogênio/sangue , Hipóxia/sangue , Análise por Pareamento , Pessoa de Meia-Idade , Doenças Vasculares Periféricas/sangue , Fator A de Crescimento do Endotélio Vascular , Fatores de Crescimento do Endotélio VascularRESUMO
Restenosis is a serious therapeutic problem after percutaneous transluminal angioplasty (PTA). Strategies for the prevention of late restenosis include the use of antiaggregatory and anticoagulant drugs, aggressive lipid-lowering, intravascular radiation and others. As some of these therapeutic options are not without side effects it is important to identify patients with an increased risk to develop restenosis. Major clinically recognizable risk factors for restenosis are advanced disease stage and female gender. Elevated plasma levels of fibrinogen, Lp(a), CRP, and migration-inducing activity appear to indicate an unfavorable clinical outcome, and so does post-interventional increase of vWF and PAI-1 antigen. For peripheral arterial disease, only one study has addressed the influence of homocysteine levels upon the restenosis rate after PTA. Although homocysteine levels were elevated in >50% of patients at entry, they were not associated with a higher restenosis rate. Currently the available data allow a rough approximation of a patient's individual risk.
Assuntos
Angioplastia Coronária com Balão/efeitos adversos , Reestenose Coronária/etiologia , Doenças Vasculares Periféricas/sangue , Doenças Vasculares Periféricas/epidemiologia , Biomarcadores/sangue , Reestenose Coronária/sangue , Reestenose Coronária/diagnóstico , Humanos , Doenças Vasculares Periféricas/diagnóstico , Prognóstico , Fatores de RiscoAssuntos
Angioplastia com Balão/efeitos adversos , Oclusão de Enxerto Vascular/etiologia , Fator de Crescimento Transformador beta/sangue , Idoso , Doença das Coronárias/sangue , Doença das Coronárias/cirurgia , Humanos , Pessoa de Meia-Idade , Inibidor 1 de Ativador de Plasminogênio/sangue , Fator de Crescimento Transformador beta1RESUMO
Two years after resection of a pancreatic glucagonoma, scintigraphy with 111indium-labeled octreotide revealed hepatic metastases in a 48-yr-old man. Hepatic metastases were also visualized by CT, whereas an additional lesion in the chest was seen only by scintigraphy. A total of 11 follow-up examinations over 46 months proved somatostatin receptor scintigraphy to monitor reliably somatostatin receptor expression, growth and dissemination of glucagonoma metastases, and to indicate therapeutic readjustment if necessary. The survival time of the patient is now >75 months, in comparison with a mean survival time of 59 months reported for metastatic glucagonoma.